• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Amentum Holdings, Inc. Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

3.450 -0.050 (-1.43%)
Delayed Quote Updated: 4:00 PM EST, Nov 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 654,085
Open 3.550
Bid (Size) 3.300 (2,000)
Ask (Size) 3.950 (500)
Prev. Close 3.500
Today's Range 3.340 - 3.550
52wk Range 3.310 - 8.480
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
November 18, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
November 12, 2026
From Immuneering Corporation
Via GlobeNewswire

Performance

52-Week Range 59.3% below 52-week high
3.450
3.3152W Low 8.4852W High
1 Week 8.7% below 1-week high
3.311W Low 3.781W High

Immuneering Corporation - Class A Common Stock (IMRX) traded between $3.31 and $8.48 over the past 52 weeks and last traded at $3.45, 59.3% below its 52-week high. Over the past week it ranged between $3.31 and $3.78.

Past 12 Months
-7.0%
-7.5%
-34.3%
-33.9%
-47.9%
-51.9%
1W -$0.26
1M -$0.28
3M -$1.80
6M -$1.77
YTD -$3.17
1Y -$3.72

IMRX was -51.9% over the past year, -33.9% over six months, -47.9% year to date, -7.0% in the last week.

12 Months vs Market
IMRX
-51.9%
DIA
+6.3%
SPY
+8.0%
QQQ
+7.5%
IWM
+13.2%

Over the past 12 months IMRX returned -51.9% versus DIA (Dow) +6.3%, SPY (S&P 500) +8.0%, QQQ (Nasdaq 100) +7.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.90× 3-mo avg
Today 654,085 3-mo avg 728.1K
1W
900.3K
1M
791.8K
3M
728.1K
6M
1.1M
YTD
1.2M
1Y
1.2M

IMRX most recently traded 654,085 shares against a 3-month average daily volume of 728.1K.

More News

Read More
News headline image
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
November 12, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
November 09, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
November 06, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
November 04, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
October 29, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
October 26, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 02, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
September 28, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the ESMO Congress 2026
September 24, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 10, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in Upcoming Investor Conferences
September 03, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 05, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
July 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 01, 2026
From Immuneering Corporation
Via GlobeNewswire
Friday's session: gap up and gap down stocks ↗
May 22, 2026
Via Chartmill
News headline image
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
April 20, 2026
From Immuneering Corporation
Via GlobeNewswire

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 3.450
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 11/19/26 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 89.49M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 89M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap